Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C8H10AsNO5 |
| Molecular Weight | 275.0903 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(=O)NC1=CC(=CC=C1O)[As](O)(O)=O
InChI
InChIKey=ODFJOVXVLFUVNQ-UHFFFAOYSA-N
InChI=1S/C8H10AsNO5/c1-5(11)10-7-4-6(9(13,14)15)2-3-8(7)12/h2-4,12H,1H3,(H,10,11)(H2,13,14,15)
| Molecular Formula | C8H10AsNO5 |
| Molecular Weight | 275.0903 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
DescriptionSources: http://www.ncbi.nlm.nih.gov/pubmed/21773306Curator's Comment: description was created based on several sources, including
http://jama.jamanetwork.com/article.aspx?articleid=264264
Sources: http://www.ncbi.nlm.nih.gov/pubmed/21773306
Curator's Comment: description was created based on several sources, including
http://jama.jamanetwork.com/article.aspx?articleid=264264
Acetarsone is a pentavalent arsenical compound with antiprotozoal and antihelmintic properties. It was first discovered in 1921 at Pasteur Institute by Ernest Fourneau, and sold under the brand name Stovarsol (fourneau is the French word for stove). Before stovarsol was used in the treatment of congenital syphilis, it had already been used in other diseases : amoebiasis, acquired syphilis, yaws, trypanosomiasis and malaria, and a formidable list of toxic manifestations can be compiled from the literature. Bender (I927) recorded six cases of poisoning with malaise, fever, cedema, jaundice, diarrhoea, albuminuria, bronchitis, coryza and skin troubles, such as diffuse erythema, dryness and pruritus. Of 232 cases of amoebiasis treated by Brown (I935) without a death, thirteen (5.6%) had toxic erythemata, some of them so severe as to amount to exfoliative dermatitis. Although its mechanism of action is not fully known, acetarsone may bind to protein-containing sulfhydryl groups located in the parasite, thereby forming lethal As-S bonds. This may prevent their functioning and eventually kill the parasite.
Approval Year
Doses
| Dose | Population | Adverse events |
|---|---|---|
220 mg 2 times / day steady-state, vaginal Recommended Dose: 220 mg, 2 times / day Route: vaginal Route: steady-state Dose: 220 mg, 2 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: F Food Status: UNKNOWN Sources: |
Disc. AE: abdominal pain, vomiting... Other AEs: confused... AEs leading to discontinuation/dose reduction: abdominal pain (1 pt) Other AEs:vomiting (1 pt) rash (1 pt) confused (1 pt) Sources: |
250 mg 1 times / day multiple, vaginal Recommended Dose: 250 mg, 1 times / day Route: vaginal Route: multiple Dose: 250 mg, 1 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: F Food Status: UNKNOWN Sources: |
Disc. AE: Exfoliative dermatitis... AEs leading to discontinuation/dose reduction: Exfoliative dermatitis (1 pt) Sources: |
500 mg 1 times / day steady-state, oral Recommended Dose: 500 mg, 1 times / day Route: oral Route: steady-state Dose: 500 mg, 1 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M Food Status: UNKNOWN Sources: |
Disc. AE: Stevens-Johnson syndrome... AEs leading to discontinuation/dose reduction: Stevens-Johnson syndrome (1 pt) Sources: |
250 mg 2 times / day steady-state, oral Studied dose Dose: 250 mg, 2 times / day Route: oral Route: steady-state Dose: 250 mg, 2 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: |
Other AEs: thrombocytosis... |
AEs
| AE | Significance | Dose | Population |
|---|---|---|---|
| confused | 1 pt | 220 mg 2 times / day steady-state, vaginal Recommended Dose: 220 mg, 2 times / day Route: vaginal Route: steady-state Dose: 220 mg, 2 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: F Food Status: UNKNOWN Sources: |
| abdominal pain | 1 pt Disc. AE |
220 mg 2 times / day steady-state, vaginal Recommended Dose: 220 mg, 2 times / day Route: vaginal Route: steady-state Dose: 220 mg, 2 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: F Food Status: UNKNOWN Sources: |
| rash | 1 pt Disc. AE |
220 mg 2 times / day steady-state, vaginal Recommended Dose: 220 mg, 2 times / day Route: vaginal Route: steady-state Dose: 220 mg, 2 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: F Food Status: UNKNOWN Sources: |
| vomiting | 1 pt Disc. AE |
220 mg 2 times / day steady-state, vaginal Recommended Dose: 220 mg, 2 times / day Route: vaginal Route: steady-state Dose: 220 mg, 2 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: F Food Status: UNKNOWN Sources: |
| Exfoliative dermatitis | 1 pt Disc. AE |
250 mg 1 times / day multiple, vaginal Recommended Dose: 250 mg, 1 times / day Route: vaginal Route: multiple Dose: 250 mg, 1 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: F Food Status: UNKNOWN Sources: |
| Stevens-Johnson syndrome | 1 pt Disc. AE |
500 mg 1 times / day steady-state, oral Recommended Dose: 500 mg, 1 times / day Route: oral Route: steady-state Dose: 500 mg, 1 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M Food Status: UNKNOWN Sources: |
| thrombocytosis | 1 pt | 250 mg 2 times / day steady-state, oral Studied dose Dose: 250 mg, 2 times / day Route: oral Route: steady-state Dose: 250 mg, 2 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: |
Sample Use Guides
In Vivo Use Guide
Sources: http://www.ncbi.nlm.nih.gov/pubmed/21773306
one to four grains
Route of Administration:
Oral
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:29:46 GMT 2025
by
admin
on
Mon Mar 31 18:29:46 GMT 2025
|
| Record UNII |
806529YU1N
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
WHO-ATC |
A07AX02
Created by
admin on Mon Mar 31 18:29:46 GMT 2025 , Edited by admin on Mon Mar 31 18:29:46 GMT 2025
|
||
|
NCI_THESAURUS |
C250
Created by
admin on Mon Mar 31 18:29:46 GMT 2025 , Edited by admin on Mon Mar 31 18:29:46 GMT 2025
|
||
|
WHO-VATC |
QG01AB01
Created by
admin on Mon Mar 31 18:29:46 GMT 2025 , Edited by admin on Mon Mar 31 18:29:46 GMT 2025
|
||
|
WHO-VATC |
QA07AX02
Created by
admin on Mon Mar 31 18:29:46 GMT 2025 , Edited by admin on Mon Mar 31 18:29:46 GMT 2025
|
||
|
WHO-VATC |
QP51AD05
Created by
admin on Mon Mar 31 18:29:46 GMT 2025 , Edited by admin on Mon Mar 31 18:29:46 GMT 2025
|
||
|
WHO-ATC |
G01AB01
Created by
admin on Mon Mar 31 18:29:46 GMT 2025 , Edited by admin on Mon Mar 31 18:29:46 GMT 2025
|
||
|
WHO-ATC |
P01CD02
Created by
admin on Mon Mar 31 18:29:46 GMT 2025 , Edited by admin on Mon Mar 31 18:29:46 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
ACETARSOL
Created by
admin on Mon Mar 31 18:29:46 GMT 2025 , Edited by admin on Mon Mar 31 18:29:46 GMT 2025
|
PRIMARY | |||
|
55
Created by
admin on Mon Mar 31 18:29:46 GMT 2025 , Edited by admin on Mon Mar 31 18:29:46 GMT 2025
|
PRIMARY | |||
|
DB13268
Created by
admin on Mon Mar 31 18:29:46 GMT 2025 , Edited by admin on Mon Mar 31 18:29:46 GMT 2025
|
PRIMARY | |||
|
DTXSID9045847
Created by
admin on Mon Mar 31 18:29:46 GMT 2025 , Edited by admin on Mon Mar 31 18:29:46 GMT 2025
|
PRIMARY | |||
|
202-582-3
Created by
admin on Mon Mar 31 18:29:46 GMT 2025 , Edited by admin on Mon Mar 31 18:29:46 GMT 2025
|
PRIMARY | |||
|
SUB05218MIG
Created by
admin on Mon Mar 31 18:29:46 GMT 2025 , Edited by admin on Mon Mar 31 18:29:46 GMT 2025
|
PRIMARY | |||
|
100000087936
Created by
admin on Mon Mar 31 18:29:46 GMT 2025 , Edited by admin on Mon Mar 31 18:29:46 GMT 2025
|
PRIMARY | |||
|
1985
Created by
admin on Mon Mar 31 18:29:46 GMT 2025 , Edited by admin on Mon Mar 31 18:29:46 GMT 2025
|
PRIMARY | |||
|
13160
Created by
admin on Mon Mar 31 18:29:46 GMT 2025 , Edited by admin on Mon Mar 31 18:29:46 GMT 2025
|
PRIMARY | |||
|
C005284
Created by
admin on Mon Mar 31 18:29:46 GMT 2025 , Edited by admin on Mon Mar 31 18:29:46 GMT 2025
|
PRIMARY | |||
|
371
Created by
admin on Mon Mar 31 18:29:46 GMT 2025 , Edited by admin on Mon Mar 31 18:29:46 GMT 2025
|
PRIMARY | |||
|
C61621
Created by
admin on Mon Mar 31 18:29:46 GMT 2025 , Edited by admin on Mon Mar 31 18:29:46 GMT 2025
|
PRIMARY | |||
|
806529YU1N
Created by
admin on Mon Mar 31 18:29:46 GMT 2025 , Edited by admin on Mon Mar 31 18:29:46 GMT 2025
|
PRIMARY | |||
|
97-44-9
Created by
admin on Mon Mar 31 18:29:46 GMT 2025 , Edited by admin on Mon Mar 31 18:29:46 GMT 2025
|
PRIMARY | |||
|
m1321
Created by
admin on Mon Mar 31 18:29:46 GMT 2025 , Edited by admin on Mon Mar 31 18:29:46 GMT 2025
|
PRIMARY | Merck Index |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
SALT/SOLVATE -> PARENT | |||
|
|
SALT/SOLVATE -> PARENT | |||
|
|
SALT/SOLVATE -> PARENT |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |